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Abstract We report the cloning and sequencing of 5'-terminal 
region of a / ]  form of rat ECE-1 cDNA which is different only 
in its N-terminal amino-acid sequence to the cDNA we have 
cloned previously (c~ form [K. Shimada et al. (1994) J. Biol. 
Chem. 269, 18275-18278]). No significant difference was found 
in the specific activity and substrate specificity between the two 
isoforms. The expression level of ECE-I~ mRNA was higher 
than that of ECE-I~ in various rat cells and tissues, suggesting 
that the physiologically important isoform is ECE-la. The pres- 
ent findings verified the presence of two forms of ECE-1 over 
many species, which are created probably through alternative 
splicing. 
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1. Introduction 
ent from the one of Schmidt et al. had reported at the 5'- 
terminus [9]. From these observations, therefore, it is pertinent 
to assume that there are two types of ECE-1 mRNAs in each 
animal species which differ by their N-termini. Yorimitsu et al. 
previously suggested the possible presence of alternatively 
spliced forms [8]. We tentatively designated each of these two 
sequences as ~ and fl form, as guided by the suggestion of 
Turner and Murphy [10]. The rat eDNA which we cloned [4], 
and bovine and human cDNAs cloned by Sehmidt et al. and 
Yorimitsu et al. [7,8] are recognized as c¢ forms while bovine 
cDNAs cloned by Xu et al. [5] and by Ikura et al. [6], and 
human eDNA which we cloned [9] are all collectively termed 
,8 forms. 
Here we report the cloning and sequencing of the Y-terminal 
region of the fl form of rat ECE-1 eDNA, and reveal that the 
c¢ form is dominant in various cells and organs. In addition, 
enzymatic properties of the two forms of ECE-1 are also exten- 
sively compared. 
Endothelins (ETs) are potent vasoconstrictive 21amino-acid 
peptides originally isolated from the supernatant of cultured 
porcine aortic endothelial cells [1]. ETs are generated by a 
unique proteolytic leavage of big endothelins (big ETs) at the 
Trp21-Va122 or Trp2~-Ile 22 bond catalyzed by an endothelin- 
converting enzyme (ECE) [2]. 
Purification and cDNA cloning studies of rat ECE-1 revealed 
that it is an unique, highly glycosylated neutral metalloprotease 
with a single transmembrane domain near the N-terminus [3,4]. 
In the light of the subsequent s udies being carried out both on 
bovine ECE-1, the results, however, were somehow in contra- 
diction to each other on the basis of their N-terminus alone; i.e. 
Xu et al. [5] and Ikura et al. [6] have cloned and sequenced one 
form of bovine ECE-1 eDNA, while Schmidt et al. have cloned 
another form of bovine ECE-1 cDNA. The latter was almost 
the same as the former except for its N-terminal 28 amino-acid 
residues [7]. Schmidt et al. went on to discuss that the sequence 
reported by Xu et al. resulted from a misinterpretation of incor- 
porated intronic sequences and does not reflect the authentic 
amino-acid sequence [7]. This speculation was further sup- 
ported by the fact that the sequence of bovine ECE-1 eDNA 
cloned by Schmidt et al. was more homologous to rat ECE-1 
sequence than the bovine sequences that others have cloned 
[4-7]. In addition, the sequence of human ECE-1 cDNAs, 
cloned by Schmidt et al. and Yorimitsu et al., were also homol- 
ogous to that of rat ECE-1 cDNA [4,7,8]. Interestingly, the 
sequence of human ECE-1 eDNA which we cloned was differ- 
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2. Materials and methods 
2.1. Cell culture 
SV40-transformed rat lung vascular endothelial cells (TRLEC-03 
cells) were kindly supplied by Dr. S. Tsurufuji, Institute of Cytosignal 
Research, Inc., and were cultured on a collagen-coated flask (Corning) 
in a RPMI-1640 medium containing 10% FCS. COS-1 cells were cul- 
tured in DMEM containing 10% FCS. Human umbilical vein endothe- 
lial cells (HUVEC) were purchased from Kurabo, Japan and cultured 
as described [11]. All cells were grown in a humidified incubator in a 
5% CO2/95% air atmosphere at37°C. All media were purchased from 
Gibco BRL and supplemented with penicillin/streptomycin. 
2.2. Cloning ofthe Y-terminal region of rat ECE-I~ eDNA and human 
ECE-I~ eDNA 
Rat lung total RNA was prepared and used for cloning of the 5'- 
terminal region of rat ECE-1//eDNA. A sense primer (GTGGGAAC- 
CAGACCACCC) was designed from the homology between the 5'- 
noncoding region of bovine and human ECE-1,8 eDNA sequences 
[5,6,9], and an antisense primer (GGGGTCCATGGAGTTTAGGA- 
TGGAGCTGGT) was based on rat ECE-lc¢ eDNA [4]. The rat ECE- 
lfl cDNA was amplified from single-stranded eDNA from rat lung total 
RNA using the sense primer and the antisense primer. Reverse tran- 
scription-PCR was performed using RNA-PCR kit (Takara Shuzo, 
Japan) according to the manufacturer's in truction. The 354 bp PCR 
product was subcloned into a pCR II TA vector (Invitrogen) and 
sequenced automatically on both strands. The EcoRI (vector)-BlnI 
(211) region of rat ECE-I~ cDNA [4] was replaced by the EcoRI 
(vector)-BlnI (235) fragment of the product o construct rat ECE-1,8 
eDNA. The resultant full length rat ECE-1]/cDNA was inserted into 
a pcDL-SRc~296 vector [12] for expression. 
The total RNA of HUVEC was prepared and used for cloning of the 
5'-terminal region of human ECE-1 c~ eDNA. The cDNA was amplified 
from single stranded HUVEC cDNA using a sense primer (atgatgaatt- 
catgcatGTGTCCGCCCCTGCTGTCGGCGCTG) and an antisense 
primer (GCAGGGGTCCACTGTGGGGTCC) which were designed 
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based on human ECE-lc~ cDNA [7]. The 360 bp PCR product was 
subcloned and sequenced as described above. Since human ECE-1~ and 
-lfl cDNA sequences are identical except for their 5'-terminal region, 
the EcoRI (vector)-HindlII (331) region of human ECE-lfl cDNA 
cloned previously [9] was replaced by the EcoRI(primer)-HindlII (292) 
fragment of the product to construct human ECE-lc~ cDNA. The 
resultant full-length human ECE-lc~ cDNA was inserted into the 
pcDL-SR~296 vector for expression. 
2.3. Northern blot analysis of human ECE-lo~ and -1~ mRNA 
Four ,ug of poly(A) + RNA prepared from HUVEC was separated by 
formaldehyde/1.0% agarose gel electrophoresis and transferred to a 
Hybond N ÷ membrane (Amersham Corp.). 5'-endlabelled oligonucleo- 
tide probe for human ECE-lc~ mRNA (GTCCACCAGGTCCTCCT- 
CGTCCAGCGTGGCCCGCTTGTACGTCGA) or for human ECE- 
lfl mRNA (CCCTTGGAGGAAGGGGTTCCGCTGCAGGCCCA- 
GGCCCTGGAGAGG) was used as a probe, respectively. Membranes 
were washed in 2×SSC, 0.1% SDS at 60°C and analyzed by BAS 2000 
system (FUJIX). 
2.4. Competitive PCR of rat ECE-la and -1~ transcripts 
The levels of rat ECE-I~ and -lfl transcripts were measured by 
competitive PCR [13] using their respective cDNAs, which were re- 
verse-transcribed from RNA samples. The 5'-terminal regions of rat 
ECE-1 e and -lfl cDNAs were synthesized by PCR using a sense primer 
(ATGATGTCATCCTACAAGCGGGCC) for ECE-lc~ cDNA, a 
sense primer (ATGGGCAGCCTGAGGCCTCCCCAG) for ECE-lfl 
cDNA, and an antisense primer (GGGTCCATGGAGTTTAGGAT- 
GGAGCTGGT) for both cDNAs, and the PCR products (303 bp for 
ECE-kz and 327 bp for ECE-lfl) were subcloned into a pCR II TA 
vector to construct pCRrECE-I~ and pCRrECE-lfl, respectively. For 
construction of competitor DNA, a vector egion of each plasmid was 
amplified using an antisense primer (CCGGGGGCTGCGAAGGTT- 
CAC) and a sense primer (CTGGTGGTTCTGGTGACGCTTCTG- 
GCAGCAGGG), and blunt-ended PCR products were self-ligated. 
The resultant plasmids, pCRrECE-le-d and pCRrECE-lfl-d, carry a 
43 bp deletion within each cDNA. These plasmids were subjected to 
PCR after their linearization with restriction enzyme digestion. 
From 100 ng of poly (A)+RNA prepared from TRLEC-03 cells or 
several rat tissues, cDNAs were synthesized using random 9mer primer 
in a total volume of 20 pl and diluted 10-fold with H20. Aliquots of 2 ¢tl 
of these dilutions were subjected to the quantitative PCR analysis in the 
presence of linearized competitor DNA using sense primer for ECE-lc~ 
or sense primer for ECE-lfl, and antisense primer for both cDNAs as 
described above. As a control, glyceraldehyde 3-phosphate dehydroge- 
nase (G3PDH) cDNA was amplified using rat G3PDH control am- 
plimer set (Clontech). 
2.5. Expression of ECE-la and -1~ in COS-1 cells 
Expression vector for rat or human ECE-la or -lfl was transfected 
into COS-1 cells. The solubilized membrane fraction was prepared from 
each cell as described previously [4]. The solubilized membrane frac- 
tions were separated on 4~20% SDS-PAGE under reducing condition, 
and transferred to polyvinylidene difluoride membrane (Millipore). 
Immunoblot analysis probed with anti-ECE-1 monoclonal antibody, 
AEC32-236, was carried out as described previously [9]. The amount 
of immunoreactive ECE-1 in each sample was determined by measure- 
ment of chemiluminescence using ARGUS-100 (Hamamatsu photoe- 
lectronics). Purified rat lung ECE-1 [3] was used as a standard. The 
enzyme reaction was carried out at 37°C for 2 h in 100/11 of reaction 
mixture consisting of 100 mM Tris-HC1 (pH 7.0), 0.1% (w/v) BSA, 
0.1 mM PMSF, 20 pM pepstatin A, 20/tM leupeptin, 4 pg of the 
solubilized membrane protein, and 0.1 lzM of human big ETs. Produced 
ETs were determined by a sandwich enzyme immunoassay [14]. 
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Fig. 1. (A) Nucleotide and deduced amino-acid sequences of cloned region of rat ECE-lfl cDNA. Primer regions used for the cloning by reverse 
transcription-PCR are underlined. Nucleotide and amino-acid sequences differ rom those of rat ECE-I~ and are boxed. Putative transmembrane 
domain is doubly underlined. Putative splicing site is indicated by an arrow. (B) Alignment of N-terminal amino-acid sequences of ECE-1 c~ and -lfl. 
Amino-acid sequences of a-form of rat [4], human and bovine [7] or r-form of rat [this paper], human [9] and bovine [6] are aligned. Homology to 
rat sequence in each form and homology between ~ and fl forms in each species are indicated. Dots indicate amino-acids identical to the respective 
rat sequences. Dashes represent amino-acid sequences identical to that of the another form of each species. 
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2.6. Indirect immunofluorescence 
COS-1 cells transfected with either human ECE-la or -lfl eDNA 
were grown on glass coverslips for 48 h. All subsequent processing was 
performed at room temperature. The cells were fixed with 3% formalde- 
hyde in PBS for 15 min, quenched with 0.1 M glycine in PBS, and 
incubated in0.1% saponin in PBS for 10 min for permeabilized samples. 
The samples were blocked with normal 10% goat serum in PBS for 1 h, 
incubated with AEC 32-236 for 1 h, washed in PBS, and then incubated 
with FITC-conjugated goat anti-mouse IgG (Jackson) for 1 h. In all 
cases, the antibodies were diluted in 10% goat serum in PBS. The 
coverslips were mounted in a 1 : 1 mixture of PBS: glycerol containing 
2% 1,4-diazabicyclo[2.2.2.]octane to prevent photobleaching. Samples 
were viewed under a Bio-Rad MRC-600 confocal fluorescence micro- 
scope (Bio-Rad) and photographed using a HC1500 film processor 
(Toshiba, Japan). 
3. Results 
3.1. Structure of ECE-lo~ and-19 
5'-terminal region of rat ECE-lfl eDNA was amplified by 
reverse-transcription PCR from rat lung RNA as described in 
section 2. A sense primer was designed from homology between 
bovine and human ECE-lfl cDNA sequences [5,6,9] and an 
antisense primer was designed based on rat ECE-1 a eDNA [4]. 
Fig. 1A shows cloned region of rat ECE-lf l  eDNA sequence 
and its deduced amino-acid sequence. The eDNA sequence 
obtained was different from that of rat ECE- la  eDNA by its 
5'-terminal 138 bp sequence, resulting in complete differentia- 
tion of the N-terminal amino-acid sequence from that of rat 
ECE-la,  although the eDNA sequence in other regions was 
completely identical to that of rat ECE-la.  Fig. 1B shows the 
alignment of N-terminal amino-acid sequences of rat, human 
and bovine ECE- la  and -lfl. ECE- la  was highly conserved 
among 3 species, whereas the homology of ECE-lfl among 3 
species was much lower than that of ECE-1 e. Complete identity 
of human ECE- la  and -lfl cDNAs except for their 5'-terminal 
regions [7-9] strongly suggests that these isoforms are produced 
by alternative splicing from the same gene. Genomic PCR was 
next carried out using either at ECE-1 a or -lfl specific primers. 
The primers used were the same as those used for quantitation 
of each mRNA described above (see [2.4]). When rat ECE- la  
specific primers were used, we obtained PCR product having 
the same size as respective cDNA, whereas no PCR product 
was synthesized when rat ECE-lfl specific primers were used 
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Fig. 2. Northern blot analysis of ECE-la and -lfl transcripts in 
HUVEC. The 5.0-kb and 3.0-kb ECE-1 mRNAs are indicated by ar- 
rows. RNA blot of 4/2g of HUVEC poly(A) ÷ RNA was hybridized with 
ECE-la specific probe (a) or ECE-Ifl specific probe (fl). Positions of 
Mr markers are shown. 
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Fig. 3. Competitive PCR analyses of ECE-la and -lfl transcripts in 
various cells and tissues. Single-stranded cDNAs were reverse-tran- 
scribed from the poly (A) ÷ RNA of various cells and tissues indicated. 
Each cDNA was subjected to ECE-1 a specific PCR (ECE-I a) or ECE- 
lfl specific PCR (ECE-1,8) in the presence of a 1 pg of competitor DNA 
for ECE-la or 0.3 pg of a competitor DNA for ECE-lfl, respectively. 
cDNAs were also subjected to G3PDH specific PCR (G3PDH). The 
amplified products were subjected to electrophoresis on agarose gels 
and were visualized by staining with ethidium bromide. 
(data not shown). Human genomic PCR was also carried out 
using either human ECE- 1 a or - lfl specific primers correspond- 
ing to the sequence used for ratgenomic PCR, and the results 
were identical with t ose of rat genomic PCR (data not shown). 
These results uggest the absence of an intronic sequence in this 
region of ECE-I~ pre-mRNA, and inversely, the presence of 
a relatively large intronic sequence in that of ECE-lfl pre- 
mRNA. Indeed, the consensus equence for a splice acceptor 
signal, (Py)nNCAG/G [15], is found in rat ECE-lc~ eDNA 
(CCCTACAG/G) [4]. Putative splicing site in ECE-lfl eDNA 
is indicated in Fig. 1A. The splice acceptor signal sequence in 
the same location is also found in the bovine and human ECE- 
lc~ cDNAs [7,8]. Comparing the human ECE-lfl eDNA, which 
we have reported previously [9] and the rat ECE-lfl cDNA 
cloned in this study, together with bovine cDNAs [5,6] indicates 
the existence of a fl form of transcript in all these species tested. 
Northern blot analysis also elucidated the presence of both 
forms of ECE- 1 mRNA in HUVEC (Fig. 2). The two different 
sizes of the mRNA are presumably generated by alternative 
poly(A) addition in the 3'-noncoding region as observed in 
bovine ECE-1 mRNA [5]. 
3.2. Determination of expression levels of ECE-I~ and-19 
mRNAs in various cells and tissues 
We next examined the expression levels of ECE-I~ and -lfl 
mRNAs in several rat tissues and cells by competitive PCR 
(Fig. 3). ECE-I~ mRNA was more abundant han ECE-lfl 
mRNA in all the tissues examined. As previously observed, 
ECE-1 mRNAs were expressed at a high level in lung and 
adrenal gland compared with other organs [4], but the ratio 
between ~ and fl in these organs was similar to that in other 
organs. In the case of TRLEC-03 cells, in particular, no ECE- 
lfl mRNA was detected. Northern blot analyses of human 
ECE-1 ~ and -lfl also clarified that ECE-1 ~ mRNA was more 
abundant than ECE-lfl mRNA in all the tissues investigated 
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(data not shown). Reverse-transcription PCR analyses on 
HUVEC RNA revealed that ECE-1 mRNA of the c~ form is 
also more abundant than that of the fl form (data not shown). 
3.3. Comparison of enzymatic properties of ECE-1 c~ and -1 [~ 
For comparison of enzymatic properties of ECE- 1 ~ and - 113, 
either ECE-I~ or -113 eDNA were expressed in COS-I cells. As 
an antibody which recognizes both ECE-I~ and -113, we here 
employed monoclonal antibody AEC32-236 [9], because it re- 
acts with truncated rat ECE-I~ which lacks the N-terminal 98 
amino-acid sequence [16] as well as intact human, rabbit and 
bovine ECE-1 [9]. Immunoblot analysis howed the presence 
of immunoreactive proteins in solubilized membrane fractions 
prepared from these cells (Fig. 4). As previously reported, 
ECE-1 is a highly glycosylated protein, but no difference was 
found in glycosylation levels of the two forms. 
Enzyme activities of these recombinant proteins were shown 
in Table 1. Both forms of ECE-1 showed almost the same 
specific activities and substrate specificities, and similar results 
were obtained when the concentration of substrates was varied 
from 0.1/zM to 2/zM (data not shown). Specific activities of 
human ECE- 1 ~ and - 113 were, however, significantly ower than 
those of rat ECE- 1 c~ and - lfl probably due to differences in their 
glycosylation levels (Fig. 4) as described previously [9]. Subcel- 
lular localizations of human ECE-I~ and -113 expressed in 
COS-1 cells were studied using AEC32-236 by confocal laser 
immunofluorecescent micrography. Both human ECE-I~ and 
-lfl were found to be mainly localized on the plasma membrane 
with the clustering structure (Fig. 5) as observed with rat ECE- 
1~ [16] without any further difference in their morphological 
feature. The result indicates that the differences in N-terminal 
amino-acid sequences between ~ and 13 do not affect their 
subcellular localization. 
4. Discussion 
In the present study, we have accomplished the cloning of 
5'-terminal region of a new rat ECE-lfl cDNA by reverse- 
transcription PCR derived from rat lung RNA. This result 
together with previous observations indicates the presence of 
two isoforms of ECE-1, whose sequences are different only in 
1 2 3 4 
(kDa) 
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85 - -  
47- -  
Fig. 4. Immunoblot analysis of ECE-lc~ and ECE-lfl. Immunoblot 
analysis was carried out using indicated amounts of membrane frac- 
tions prepared from COS-1 cells transfected with rat ECE-I~t eDNA, 
2.5 pg (lane 1), rat ECE-lfl eDNA, 2.5/zg (lane 2), human ECE-10~ 
eDNA, 2.0/zg (lane 3) and human ECE-lfl cDNA, 2.0/.tg (lane 4). 
Positions of Mr markers are shown. 
Fig. 5. Subcellular localization of ECE-1 by confocal laser immunofluo- 
rescent analysis. COS-1 cells transfected with human ECE-lc~ cDNA 
(a) or ECE-lfl cDNA (b) were fixed and permeabilized for both cell- 
surface and intracellular staining. Bar, 10/zm. 
the N-termini over many species. Both isoforms were also de- 
tected by Northern blotting of HUVEC RNA. These isoforms 
are probably produced by alternative splicing and/or alterna- 
tive promoter. Sequence analysis of the ECE-1 genomic DNA 
will reveal the mechanism ofthe production of ECE-1 isoforms. 
Neutral endopeptidase 24.11 (NEP), which is also a mem- 
brane-bound neutral metalloprotease and has sequence and 
structural homology to ECE-1 [4,5], exhibits a broad tissue 
distribution [17]. Li et al. demonstrated three alternatively 
spliced forms of rat NEP mRNA. In this case, each contains 
unique 5'-untranslated sequences including a promoter region 
but having a common coding sequence. The expressions of 
these transcripts are regulated in a cell- and tissue-specific man- 
ner [18]. In the case of ECE-1, the sequences of two forms of 
mRNA are different in the 5'-untranslated sequence which 
probably includes both a promoter region and a small coding 
region, but mRNA of c~ form is always 5- to 10-fold more 
abundant than mRNA offl form in any cells and organs exam- 
ined, and little tissue-specificity was observed. The observation 
that ~ is a dominant form probably reflects the fact that two 
forms exist in the one cell, yet a possibility remains that the cells 
expressing only the ~ form are much more abundant than the 
cells expressing the fl form only. In TRLEC-03 cells, no ECE-lfl 
mRNA was detected. It is possible that the transformation f 
the cells by SV-40 DNA resulted in down-regulation f ECE-lfl 
mRNA. Schmidt et al. cloned 5'-terminal cDNAs of both 
human and bovine ECE-1 ~ by rapid amplification ofthe cDNA 
ends (RACE) method [7]. This method would result in amplifi- 
cation of only the dominant form of cDNA when several alter- 
natively spliced mRNAs with similar sizes are present in the 
sample. Our results presented here well explain why they cloned 
only c~-type of ECE-1 cDNAs of both bovine and human. 
Table 1 
Specific activities and substrate specificities ofrat and human ECE-I~ 
and -lfl 
Substrate Rat Human 
Big ET-1 42* (100%) 35 (100%) 3.6 (100%) 3.4 (100%) 
Big ET-2 15 (36%) 13 (36%) 1.9 (52%) 1.7 (50%) 
Big ET-3 21 (50%) 17 (47%) 1.7 (48%) 1.5 (45%) 
Specific activities for big ET-1 are set to 100%. 
*Specific activity (nmol/h.mg). 
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The present results indicate that ECE- la  plays a major role 
for the conversion of big ETs to ETs compared to ECE-lfl. The 
significance of ECE-lfl 's presence as a minor form is unclear 
so far, as there is no difference between the two forms in specific 
activity, substrate specificity and subcellular localization. 
ECE-1 forms a disulfide-linked dimeric structure as revealed by 
our recent observation i  SDS-PAGE analyses and cross-link- 
ing experiment [16]. It is possible that ECE-1 exists as either 
homodimer (aa or tiff) or heterodimer (aft) in native cells. 
Recombinant ECE-1 a and -lfl, which is present only as respec- 
tive homodimer, showed both almost same specific activities 
and substrate specificities. These results coincide with the struc- 
tural feature of ECE- 1, that the large C-terminal region, prob- 
ably externally facing the plasma membrane, contains a cata- 
lytic domain, whereas the small cytoplasmic N-terminal region 
may not contribute to its catalytic activity [4,16]. In some type 
II membrane-anchored proteins, the N-terminal amino-acid 
sequence plays an important role for subcellular localization of 
the protein [19]. No difference was observed, however, in 
subcellular localization of ECE- la  and -lfl as far as homod- 
imers ot~ and tiff were concerned. The role of N-terminus in 
heterodimer, if any, remains to be elucidated. 
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